Pfizer said a large trial found that its Paxlovid treatment was not effective at preventing infection in people living with someone who had been exposed to the virus.

Pfizer began a rolling submission with Health Canada in December for Paxlovid, which it said is designed to block a key enzyme needed for the COVID-19 virus to multiply.